All In Biotech

Drug Trial Radar · NCT06495944

Impact of Itraconazole on the Pharmacokinetics and Safety of Dazucorilant in Healthy, Adult Participants

An Open-Label, Single-Sequence Crossover, Drug-Drug Interaction Study to Characterize the Impact of the Cytochrome P450 3A Inhibitor Itraconazole on the Pharmacokinetics and Safety of Dazucorilant in Healthy, Adult Subjects

Last checked: Nov 19, 2026Latest source record: Jul 1, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

21

Actual

Start

May 31, 2024

Primary completion

Aug 2, 2024

Study completion Aug 2, 2024

Sponsor

Lead sponsor
Corcept TherapeuticsIndustry
Sponsor type
Industry
First posted
Jul 11, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 60 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This study aims to answer how repeat doses of itraconazole impact the pharmacokinetics, safety, and tolerability of single doses of dazucorilant in healthy adults. Participants in this study will complete screening assessments within 28 days before the first dose of study drug. Those participants who can participate will be admitted to the clinical pharmacology center (CPC) and complete pretreatment tests. Those participants will stay at the CPC for the duration of the study. On Days 1 and 8, each participant will receive a single oral dose of dazucorilant 300 mg, after eating. On Days 5-11, all participants will receive once daily, oral doses of itraconazole 200 mg, after eating. Blood and safety assessments will continue for 96-hours after dosing on Day 1 and Day 8. Participants will leave the CPC following completion of all procedures on Day 12. Participants will return to the CPC for a final visit 7 (±1) days after their final dose of study medication.

Conditions

  • Healthy Adults

Interventions

  • DazucorilantDrug

    75 mg soft gelatin capsules formulation for oral administration

  • ItraconazoleDrug

    100 mg capsules for oral administration

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Maximum observed plasma concentration (Cmax) of dazucorilantTime frame: Predose and at serial timepoints up to 96 hours after dazucorilant dosing on Days 1 and 8
  2. Area under the concentration-time curve from time 0 to the last measurable concentration (AUClast) of plasma dazucorilantTime frame: Predose and at serial timepoints up to 96 hours after dazucorilant dosing on Days 1 and 8
  3. Area under the concentration-time curve from time 0 extrapolated to infinity (AUCinf) of plasma dazucorilantTime frame: Predose and at serial timepoints up to 96 hours after dazucorilant dosing on Days 1 and 8

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Site 01

    Baltimore, Maryland

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.